Chondrocyte responses to neurovascular peptides, cytokines, and a 3D environment: focus on ADAMs

References

• Konttinen YT, Sillat T, Barreto G, Ainola M, Nordstrom DC. Osteoarthritis as an autoinflammatory disease caused by chondrocyte-mediated inflammatory responses. Arthritis Rheum. 2012;64(3):613–616.
   PubMed Web of Science ®Google Scholar
• Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta. 2012;1824(1):133–145.
   PubMed Web of Science ®Google Scholar
• Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–1707.
   PubMed Web of Science ®Google Scholar
• Clockaerts S, Bastiaansen-Jenniskens YM, Runhaar J, et al. The infrapatellar fat pad should be considered as an active osteoarthritic joint tissue: a narrative review. Osteoarthritis Cartilage. 2010;18(7):876–882.
   PubMed Web of Science ®Google Scholar
• Thoms BL, Murphy CL. Inhibition of hypoxia-inducible factor-targeting prolyl hydroxylase domain-containing protein 2 (PHD2) enhances matrix synthesis by human chondrocytes. J Biol Chem. 2010;285(27):20472–20480.
   PubMed Web of Science ®Google Scholar
• Strobel S, Loparic M, Wendt D, et al. Anabolic and catabolic responses of human articular chondrocytes to varying oxygen percentages. Arthritis Res Ther. 2010;12(2):R34.
   Web of Science ®Google Scholar
• Lafont JE, Talma S, Hopfgarten C, Murphy CL. Hypoxia promotes the differentiated human articular chondrocyte phenotype through SOX9-dependent and -independent pathways. J Biol Chem. 2008;283(8):4778–4786.
   PubMed Web of Science ®Google Scholar
• Murphy CL, Thoms BL, Vaghjiani RJ, Lafont JE. Hypoxia. HIF-mediated articular chondrocyte function: prospects for cartilage repair. Arthritis Res Ther. 2009;11(1):213.
   PubMed Web of Science ®Google Scholar
• Suri S, Gill SE, Massena de Camin S, Wilson D, McWilliams DF, Walsh DA. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Ann Rheum Dis. 2007;66(11):1423–1428.
   PubMed Web of Science ®Google Scholar
• Walsh DA, McWilliams DF, Turley MJ, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford). 2010;49(10):1852–1861.
   PubMed Web of Science ®Google Scholar
• Grassel SG. The role of peripheral nerve fibers and their neurotransmitters in cartilage and bone physiology and pathophysiology. Arthritis Res Ther. 2014;16(6):485.
   PubMed Web of Science ®Google Scholar
• Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: the cytokine connection. Cytokine. 2014;70(2):185–193.
   PubMed Web of Science ®Google Scholar
• Im HJ, Li X, Muddasani P, et al. Basic fibroblast growth factor accelerates matrix degradation via a neuro-endocrine pathway in human adult articular chondrocytes. J Cell Physiol. 2008;215(2):452–463.
   PubMed Web of Science ®Google Scholar
• Meini S, Maggi CA. Knee osteoarthritis: a role for bradykinin? Inflamm Res. 2008;57(8):351–361.
   PubMed Web of Science ®Google Scholar
• Song IH, Althoff CE, Hermann KG, et al. Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI. Ann Rheum Dis. 2009;68(1):75–83.
   PubMed Web of Science ®Google Scholar
• Meini S, Cucchi P, Catalani C, Bellucci F, Giuliani S, Maggi CA. Bradykinin and B(2) receptor antagonism in rat and human articular chondrocytes. Br J Pharmacol. 2011;162(3):611–622.
   Web of Science ®Google Scholar
• Nishimura M, Segami N, Kaneyama K, Suzuki T, Miyamaru M. Relationships between pain-related mediators and both synovitis and joint pain in patients with internal derangements and osteoarthritis of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94(3):328–332.
   PubMed Web of Science ®Google Scholar
• Kaufman GN, Zaouter C, Valteau B, Sirois P, Moldovan F. Nociceptive tolerance is improved by bradykinin receptor B1 antagonism and joint morphology is protected by both endothelin type A and bradykinin receptor B1 antagonism in a surgical model of osteoarthritis. Arthritis Res Ther. 2011;13(3):R76.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou Y, Li J, Shan LQ, Fan QY. The effect of bradykinin B2 receptor polymorphisms on the susceptibility and severity of osteoarthritis in a Chinese cohort. J Biomed Biotechnol. 2012;2012:597637.
   Google Scholar
• Morales TI. Chondrocyte moves: clever strategies? Osteoarthritis Cartilage. 2007;15(8):861–871.
   Web of Science ®Google Scholar
• Opolka A, Straub RH, Pasoldt A, Grifka J, Grassel S. Substance P and norepinephrine modulate murine chondrocyte proliferation and apoptosis. Arthritis Rheum. 2012;64(3):729–739.
   Google Scholar
• Stanton H, Melrose J, Little CB, Fosang AJ. Proteoglycan degradation by the ADAMTS family of proteinases. Biochim Biophys Acta. 2011;1812(12):1616–1629.
   Web of Science ®Google Scholar
• Gendron C, Kashiwagi M, Lim NH, et al. Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem. 2007;282(25):18294–18306.
   Web of Science ®Google Scholar
• Santamaria S, Yamamoto K, Botkjaer K, et al. Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2). Biochem J. 2015;471(3):391–401.
   Google Scholar
• Larkin J, Lohr TA, Elefante L, et al. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 2015;23(8):1254–1266.
   PubMed Web of Science ®Google Scholar
• Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005;434(7033):648–652.
   PubMed Web of Science ®Google Scholar
• Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005;434(7033):644–648.
   PubMed Web of Science ®Google Scholar
• Shiomi T, Lemaitre V, D’Armiento J, Okada Y. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int. 2010;60(7):477–496.
   PubMed Web of Science ®Google Scholar
• Dreymueller D, Pruessmeyer J, Groth E, Ludwig A. The role of ADAM-mediated shedding in vascular biology. Eur J Cell Biol. 2012;91(6–7):472–485.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.
   PubMed Web of Science ®Google Scholar
• Okada A, Mochizuki S, Yatabe T, et al. ADAM-12 (meltrin alpha) is involved in chondrocyte proliferation via cleavage of insulin-like growth factor binding protein 5 in osteoarthritic cartilage. Arthritis Rheum. 2008;58(3):778–789.
   Google Scholar
• Swingler TE, Waters JG, Davidson RK, et al. Degradome expression profiling in human articular cartilage. Arthritis Res Ther. 2009;11(3):R96.
   Web of Science ®Google Scholar
• Kelly K, Hutchinson G, Nebenius-Oosthuizen D, et al. Metalloprotease-disintegrin ADAM8: expression analysis and targeted deletion in mice. Dev Dyn. 2005;232(1):221–231.
   Web of Science ®Google Scholar
• Zack MD, Melton MA, Stock JL, et al. Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8). Clin Exp Immunol. 2009;158(2):246–256.
   Web of Science ®Google Scholar
• Zack MD, Malfait AM, Skepner AP, et al. ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271). Arthritis Rheum. 2009;60(9):2704–2713.
   Google Scholar
• Stanton H, Ung L, Fosang AJ. The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. Biochem J. 2002;364(Pt 1):181–190.
   PubMedGoogle Scholar
• Flannery CR, Little CB, Caterson B, Hughes CE. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol. 1999;18(3):225–237.
   PubMed Web of Science ®Google Scholar
• Djouad F, Delorme B, Maurice M, et al. Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes. Arthritis Res Ther. 2007;9(2):R33.
   PubMed Web of Science ®Google Scholar
• Chubinskaya S, Mikhail R, Deutsch A, Tindal MH. ADAM-10 protein is present in human articular cartilage primarily in the membrane-bound form and is upregulated in osteoarthritis and in response to IL-1alpha in bovine nasal cartilage. J Histochem Cytochem. 2001;49(9):1165–1176.
   PubMed Web of Science ®Google Scholar
• Nakazora S, Matsumine A, Iino T, et al. The cleavage of N-cadherin is essential for chondrocyte differentiation. Biochem Biophys Res Commun. 2010;400(4):493–499.
   Web of Science ®Google Scholar
• Valdes AM, Hart DJ, Jones KA, et al. Association study of candidate genes for the prevalence and progression of knee osteoarthritis. Arthritis Rheum. 2004;50(8):2497–2507.
   PubMed Web of Science ®Google Scholar
• Wang L, Guo L, Tian F, Hao R, Yang T. Analysis of single nucleotide polymorphisms within ADAM12 and risk of knee osteoarthritis in a Chinese Han population. Biomed Res Int. 2015;2015:518643.
   Web of Science ®Google Scholar
• Bohm BB, Aigner T, Gehrsitz A, Blobel CP, Kalden JR, Burkhardt H. Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage. Arthritis Rheum. 1999;42(9):1946–1950.
   PubMedGoogle Scholar
• Bohm BB, Aigner T, Roy B, Brodie TA, Blobel CP, Burkhardt H. Homeostatic effects of the metalloproteinase disintegrin ADAM15 in degenerative cartilage remodeling. Arthritis Rheum. 2005;52(4):1100–1109.
   Google Scholar
• Bohm B, Hess S, Krause K, et al. ADAM15 exerts an antiapoptotic effect on osteoarthritic chondrocytes via up-regulation of the X-linked inhibitor of apoptosis. Arthritis Rheum. 2010;62(5):1372–1382.
   Google Scholar
• Fried D, Bohm BB, Krause K, Burkhardt H. ADAM15 protein amplifies focal adhesion kinase phosphorylation under genotoxic stress conditions. J Biol Chem. 2012;287(25):21214–21223.
   Web of Science ®Google Scholar
• Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45(2):146–169.
   PubMed Web of Science ®Google Scholar
• Oldefest M, Dusterhoft S, Desel C, et al. Secreted Frizzled-related protein 3 (sFRP3)-mediated suppression of interleukin-6 receptor release by A disintegrin and metalloprotease 17 (ADAM17) is abrogated in the osteoarthritis-associated rare double variant of sFRP3. Biochem J. 2015;468(3):507–518.
   Google Scholar
• Zheng Y, Saftig P, Hartmann D, Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem. 2004;279(41):42898–42906.
   Web of Science ®Google Scholar
• Zhang Z, Jin W, Beckett J, Otto T, Moed B. A proteomic approach for identification and localization of the pericellular components of chondrocytes. Histochem Cell Biol. 2011;136(2):153–162.
   Web of Science ®Google Scholar
• Mochizuki S, Shimoda M, Shiomi T, Fujii Y, Okada Y. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun. 2004;315(1):79–84.
   PubMed Web of Science ®Google Scholar
• Mitsui Y, Mochizuki S, Kodama T, et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 2006;66(20):9913–9920.
   Web of Science ®Google Scholar
• Jowett JB, Okada Y, Leedman PJ, et al. ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-alpha. Immunol Cell Biol. 2012;90(10):966–973.
   Web of Science ®Google Scholar
• Worley JR, Baugh MD, Hughes DA, et al. Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem. 2003;278(51):51340–51346.
   Web of Science ®Google Scholar
• Hikichi Y, Yoshimura K, Takigawa M. All-trans retinoic acid-induced ADAM28 degrades proteoglycans in human chondrocytes. Biochem Biophys Res Commun. 2009;386(2):294–299.
   Web of Science ®Google Scholar
• Bellucci F, Meini S, Cucchi P, et al. Synovial fluid levels of bradykinin correlate with biochemical markers for cartilage degradation and inflammation in knee osteoarthritis. Osteoarthritis Cartilage. 2013;21(11):1774–1780.
   Web of Science ®Google Scholar
• Schafer B, Marg B, Gschwind A, Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem. 2004;279(46):47929–47938.
   Web of Science ®Google Scholar
• Baker N, Sharpe P, Culley K, et al. Dual regulation of metalloproteinase expression in chondrocytes by Wnt-1-inducible signaling pathway protein 3/CCN6. Arthritis Rheum. 2012;64(7):2289–2299.
   Google Scholar
• Murray MY, Birkland TP, Howe JD, et al. Macrophage migration and invasion is regulated by MMP10 expression. PLoS One. 2013;8(5):e63555.
   Web of Science ®Google Scholar
• Stokes DG, Liu G, Dharmavaram R, Hawkins D, Piera-Velazquez S, Jimenez SA. Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility-group box (SOX) transcription factors. Biochem J. 2001;360(Pt 2):461–470.
   Google Scholar
• Barbolina MV, Adley BP, Kelly DL, et al. Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion. Int J Cancer. 2009;125(4):816–825.
   Web of Science ®Google Scholar
• Branco da Cunha C, Klumpers DD, Li WA, et al. Influence of the stiffness of three-dimensional alginate/collagen-I interpenetrating networks on fibroblast biology. Biomaterials. 2014;35(32):8927–8936.
   PubMed Web of Science ®Google Scholar
• Tsuchida AI, Beekhuizen M, t Hart MC, et al. Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes. Arthritis Res Ther. 2014;16(5):441.
   Web of Science ®Google Scholar
• Cawston TE, Ellis AJ, Humm G, Lean E, Ward D, Curry V. Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture. Biochem Biophys Res Commun. 1995;215(1):377–385.
   Web of Science ®Google Scholar
• Litherland GJ, Hui W, Elias MS, et al. Glycogen synthase kinase 3 inhibition stimulates human cartilage destruction and exacerbates murine osteoarthritis. Arthritis Rheumatol. 2014;66(8):2175–2187.
   PubMed Web of Science ®Google Scholar
• Etique N, Verzeaux L, Dedieu S, Emonard H. LRP-1: a checkpoint for the extracellular matrix proteolysis. Biomed Res Int. 2013;2013:152163.
   Google Scholar
• Wang S, Guo X, Wu XM, Lammi MJ. Genome-wide gene expression analysis suggests an important role of suppressed immunity in pathogenesis of Kashin-Beck disease. PLoS One. 2012;7(1):e28439.
   Web of Science ®Google Scholar
• Gatsios P, Haubeck HD, Van de Leur E, et al. Oncostatin M differentially regulates tissue inhibitors of metalloproteinases TIMP-1 and TIMP-3 gene expression in human synovial lining cells. Eur J Biochem. 1996;241(1):56–63.
   Google Scholar
• Singh RJ, Mason JC, Lidington EA, et al. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res. 2005;67(1):39–49.
   Web of Science ®Google Scholar
• Sahebjam S, Khokha R, Mort JS. Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum. 2007;56(3):905–909.
   PubMed Web of Science ®Google Scholar
• Su SL, Yang HY, Lee HS, et al. Gene-gene interactions between TGF-beta/Smad3 signalling pathway polymorphisms affect susceptibility to knee osteoarthritis. BMJ Open. 2015;5(6):e007931.
   PubMed Web of Science ®Google Scholar
• van Meegeren ME, Roosendaal G, Jansen NW, et al. IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage. Osteoarthritis Cartilage. 2012;20(7):764–772.
   Web of Science ®Google Scholar
• Wojdasiewicz P, Poniatowski LA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014:561459.
   PubMed Web of Science ®Google Scholar
• Liu X, Liu R, Croker BA, Lawlor KE, Smyth GK, Wicks IP. Distinctive pro-inflammatory gene signatures induced in articular chondrocytes by oncostatin M and IL-6 are regulated by Suppressor of Cytokine Signaling-3. Osteoarthritis Cartilage. 2015;23(10):1743–1754.
   PubMed Web of Science ®Google Scholar
• Gomes WF, Lacerda AC, Mendonca VA, et al. Effect of exercise on the plasma BDNF levels in elderly women with knee osteoarthritis. Rheumatol Int. 2014;34(6):841–846.
   PubMed Web of Science ®Google Scholar
• Modeer T, Anduren I, Yucel-Lindberg T. Bradykinin synergistically stimulates interleukin 6 production in human gingival fibroblasts challenged with interleukin 1 or tumour necrosis factor alpha. Cytokine. 1998;10(1):26–31.
   Web of Science ®Google Scholar
• Meini S, Cucchi P, Tinti L, et al. Fasitibant prevents the bradykinin and interleukin 1beta synergism on prostaglandin E(2) release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(8):777–786.
   Web of Science ®Google Scholar
• Gao W, McCormick J, Connolly M, Balogh E, Veale DJ, Fearon U. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1275–1283.
   PubMed Web of Science ®Google Scholar
• Shirasuna K, Shimamura N, Seno K, et al. Moderate hypoxia down-regulates interleukin-6 secretion and TLR4 expression in human Sw.71 placental cells. Cell Physiol Biochem. 2015;36(6):2149–2160.
   Google Scholar